
|Videos|November 16, 2016
- NSCLC (Issue 11)
- Volume 4
- Issue 2
The Significance of Surgery Quality in NSCLC
Author(s)Raymond Osarogiagbon, MD
Raymond Osarogiagbon, MD, medical oncologist, Baptist Memorial Medical Group, discusses the significance of surgery quality in non-small cell lung cancer (NSCLC).
Advertisement
Articles in this issue
about 9 years ago
Erlotinib Plus Bevacizumab in EGFR-Mutant NSCLCabout 9 years ago
Clinical Trials Exploring Bevacizumab in NSCLCabout 9 years ago
Expert Explores Treatments for Biomarker-Negative Lung Cancerabout 9 years ago
Erlotinib/Bevacizumab Combo Warrants Consideration for EGFR+ NSCLCabout 9 years ago
Practice-Changing Translational Advances Predicted for NSCLCabout 9 years ago
Addressing the Challenges of Treating Non-Driver NSCLCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
3
Targeting HER2-Low Breast Cancer: the ARX788 Phase 2 Clinical Trial
4
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
5







































